CN107982270A - 治疗乳腺癌的方法 - Google Patents

治疗乳腺癌的方法 Download PDF

Info

Publication number
CN107982270A
CN107982270A CN201711383372.7A CN201711383372A CN107982270A CN 107982270 A CN107982270 A CN 107982270A CN 201711383372 A CN201711383372 A CN 201711383372A CN 107982270 A CN107982270 A CN 107982270A
Authority
CN
China
Prior art keywords
entinostat
exemestane
treatment
therapy
protein lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711383372.7A
Other languages
English (en)
Chinese (zh)
Inventor
R.古德诺
P.奥登特里科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syndax Pharmaceuticals Inc
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107982270(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of CN107982270A publication Critical patent/CN107982270A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201711383372.7A 2011-09-02 2012-08-31 治疗乳腺癌的方法 Pending CN107982270A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161530873P 2011-09-02 2011-09-02
US61/530,873 2011-09-02
US201161532534P 2011-09-08 2011-09-08
US61/532,534 2011-09-08
US201161628999P 2011-11-12 2011-11-12
US61/628,999 2011-11-12
US201161568110P 2011-12-07 2011-12-07
US61/568,110 2011-12-07
CN201280053368.3A CN103906837A (zh) 2011-09-02 2012-08-31 治疗乳腺癌的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280053368.3A Division CN103906837A (zh) 2011-09-02 2012-08-31 治疗乳腺癌的方法

Publications (1)

Publication Number Publication Date
CN107982270A true CN107982270A (zh) 2018-05-04

Family

ID=47756940

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201711383372.7A Pending CN107982270A (zh) 2011-09-02 2012-08-31 治疗乳腺癌的方法
CN202110805646.7A Pending CN114053284A (zh) 2011-09-02 2012-08-31 治疗乳腺癌的方法
CN201280053368.3A Pending CN103906837A (zh) 2011-09-02 2012-08-31 治疗乳腺癌的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110805646.7A Pending CN114053284A (zh) 2011-09-02 2012-08-31 治疗乳腺癌的方法
CN201280053368.3A Pending CN103906837A (zh) 2011-09-02 2012-08-31 治疗乳腺癌的方法

Country Status (15)

Country Link
US (2) US10226472B2 (https=)
EP (2) EP2751267B1 (https=)
JP (2) JP6195384B2 (https=)
KR (1) KR101956861B1 (https=)
CN (3) CN107982270A (https=)
AU (2) AU2012301616B2 (https=)
BR (1) BR112014005080A2 (https=)
CA (1) CA2847348A1 (https=)
EA (1) EA201201474A1 (https=)
ES (1) ES2663407T3 (https=)
GE (1) GEP201706612B (https=)
HK (1) HK1254859A1 (https=)
MX (1) MX358254B (https=)
UA (6) UA123212U (https=)
WO (1) WO2013033656A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358254B (es) 2011-09-02 2018-08-10 Syndax Pharmaceuticals Inc Métodos para el tratamiento de cáncer de mama.
KR102337598B1 (ko) * 2013-05-03 2021-12-10 신닥스 파마슈티컬스, 인크. 암 치료 방법
US20180104232A1 (en) * 2015-03-12 2018-04-19 The University Of Chicago Methods for determining prognosis for breast cancer patients
BR112018003238A2 (en) * 2015-09-02 2018-09-25 Syndax Pharmaceuticals, Inc. patient selection for combination therapy
JP7158104B2 (ja) 2016-07-15 2022-10-21 ビラクタ セラピューティクス，インク． Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
CN111278459A (zh) 2017-05-19 2020-06-12 赛达克斯制药股份有限公司 组合疗法
KR20250115460A (ko) 2018-05-07 2025-07-30 신닥스 파마슈티컬스, 인크. 병용 요법을 위한 환자의 선정
KR102212699B1 (ko) 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154382A1 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090048156A1 (en) * 2007-06-06 2009-02-19 Angela Brodie Hdac inhibitors and hormone targeted drugs for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2008021542A2 (en) 2006-08-17 2008-02-21 Cell Signaling Technology, Inc. Lysine acteylation sites
WO2009067500A1 (en) 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
KR20140012080A (ko) 2011-02-02 2014-01-29 제넨테크, 인크. 항-egfl7 항체를 사용하는 치료를 위한 투여
MX358254B (es) 2011-09-02 2018-08-10 Syndax Pharmaceuticals Inc Métodos para el tratamiento de cáncer de mama.
CH706458B1 (fr) 2012-04-30 2017-05-15 Granit Tech Sa Procédé de cimentation pour le stockage de déchets.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008154382A1 (en) * 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20090048156A1 (en) * 2007-06-06 2009-02-19 Angela Brodie Hdac inhibitors and hormone targeted drugs for the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A M WARDLEY 等: "Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor , in patients whose breast cancer is progressing on aromatase inhibitor therapy", 《JOURNAL OF CLINICAL ONCOLOGY AMERICAN SOCIETY OF CLINICAL ONCOLOGY》 *

Also Published As

Publication number Publication date
GEP201706612B (en) 2017-02-10
EP3381454A1 (en) 2018-10-03
AU2018203059A1 (en) 2018-05-17
KR20140108629A (ko) 2014-09-12
KR101956861B1 (ko) 2019-03-12
BR112014005080A2 (pt) 2017-03-28
US20190343844A1 (en) 2019-11-14
JP2017149761A (ja) 2017-08-31
JP2014525465A (ja) 2014-09-29
MX358254B (es) 2018-08-10
EP2751267B1 (en) 2018-01-24
UA124240U (uk) 2018-03-26
EA201201474A1 (ru) 2013-08-30
EP2751267A4 (en) 2015-01-07
ES2663407T3 (es) 2018-04-12
CN114053284A (zh) 2022-02-18
UA149007U (uk) 2021-10-13
AU2012301616A1 (en) 2014-04-17
UA123212U (uk) 2018-02-26
UA124239U (uk) 2018-03-26
CN103906837A (zh) 2014-07-02
MX2014002515A (es) 2015-05-07
UA124241U (uk) 2018-03-26
EP2751267A1 (en) 2014-07-09
HK1254859A1 (zh) 2019-07-26
US20140378420A1 (en) 2014-12-25
AU2012301616B2 (en) 2018-02-08
JP6195384B2 (ja) 2017-09-13
UA124238U (uk) 2018-03-26
US10226472B2 (en) 2019-03-12
WO2013033656A1 (en) 2013-03-07
CA2847348A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
CN107982270A (zh) 治疗乳腺癌的方法
BR112017020002A2 (en) COMBINATION OF HDAC INHIBITOR AND ANTI-PD-1 ANTIBODY FOR CANCER TREATMENT
CN107921108A (zh) 用于治疗癌症的hdac抑制剂和抗‑pd‑l1抗体的组合
JP6860949B2 (ja) 癌の処置方法
US20190290759A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
US20260041695A1 (en) Combination therapies for treatment of breast cancer
KR20210105388A (ko) 암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
US20130150386A1 (en) Methods for the treatment of lung cancer
CA2980297C (en) Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer
UA144014U (uk) Набір для лікування стійкого до інгібітора ароматази раку молочної залози

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254859

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180504

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1254859

Country of ref document: HK